Gonadorelin: Side Effects

Safety Notice#

The safety profile of Gonadorelin in humans has not been established through controlled clinical trials. The information below is derived primarily from animal studies and should be interpreted accordingly.

Documented Adverse Effects#

Summary of available evidence

• Acute toxicity (LD50): Veterinary product collateral reports LD50 values exceeding the tested ranges: in mice and rats, LD50 >60 mg/kg; in dogs, LD50 >600 mcg/kg. The route is not specified in the retrieved excerpt. These thresholds indicate low acute lethality at tested ranges (herdUnknownyeartimelyefficientreproduction pages 4-4).
• Repeat-dose/organ toxicity: Short-term intravenous repeat-dose studies reported no adverse findings at tested doses: rats tolerated 120 mcg/kg/day IV for 15 days without adverse effects; dogs tolerated 72 mcg/kg/day IV for 15 days without adverse effects. A statement also notes no adverse cardiovascular effects (e.g., heart rate, blood pressure) under the study conditions (herdUnknownyeartimelyefficientreproduction pages 4-4).
• Genotoxicity/mutagenicity: No Ames test, in vitro mammalian cell, or in vivo genotoxicity/micronucleus results were reported in the retrieved sources; therefore, mutagenicity cannot be assessed from the present evidence (herdUnknownyeartimelyefficientreproduction pages 4-4).
• Carcinogenicity: No carcinogenicity studies or outcomes were reported in the retrieved sources (herdUnknownyeartimelyefficientreproduction pages 4-4).
• Reproductive/developmental toxicity: In veterinary labeling context, gonadorelin is pharmacologically active and can induce abortion depending on gestational stage; product materials indicate that the ability to induce abortion decreases beyond approximately five months of gestation, with increasing dystocia risk. This reflects expected pharmacology of GnRH rather than intrinsic organ toxicity but is relevant to developmental outcomes in gravid animals (herdUnknownyeartimelyefficientreproduction pages 4-4).
• Dose–response relationships: Therapeutic dosing in cattle is in the microgram range (e.g., 43–86 mcg per cow IM/IV for reproductive indications), whereas nonclinical short-term IV studies in rats and dogs reported no adverse effects at 72–120 mcg/kg/day for 15 days, and LD50 thresholds in rodents are more than 60 mg/kg, indicating a wide margin between pharmacologic doses and doses associated with lethality in animals. Precise NOAEL/LOAEL values were not defined beyond the “no adverse effects” statements at the cited doses (herdUnknownyeartimelyefficientreproduction pages 4-4).

Key limitations

• The LD50 routes were not specified in the retrieved excerpt.
• No primary mutagenicity/genotoxicity or carcinogenicity data were found in the retrieved sources; fuller assessment would require access to formal labels (e.g., DailyMed, SmPC) or nonclinical study reports.

Embedded summary table of evidence

Conclusion Based on the retrieved veterinary product materials, gonadorelin shows low acute lethality in standard species at tested ranges (LD50 >60 mg/kg in rodents; >600 mcg/kg in dogs), no adverse findings in short IV repeat-dose studies in rats and dogs at microgram-per-kg daily doses for two weeks, and expected pharmacologic effects on reproduction, including induction of abortion in gravid animals. Genotoxicity and carcinogenicity results were not available in the retrieved excerpts; additional regulatory labeling or study reports would be needed to complete those endpoints (herdUnknownyeartimelyefficientreproduction pages 4-4).

Human Safety Reports#

• Human data (native gonadorelin; general GnRH use): A pharmacology review lists common, usually mild reactions with diagnostic/therapeutic GnRH (gonadorelin): headache, flushing, nausea, local injection‑site swelling, and rhinitis with nasal administration. These are described qualitatively as common and transient; specific percentages were not provided in the source reviewed (qualitative frequency).

• Human case report (native gonadorelin, IV): An immunoglobulin‑mediated hypersensitivity/anaphylaxis has been reported after intravenous gonadorelin acetate. The reaction occurred within minutes and required epinephrine and supportive care. Frequency is characterized as exceedingly rare in the review summarizing such reports; severity is life‑threatening.

• Human class effects (GnRH agonists/analogs; not native gonadorelin): Reviews of GnRH agonist therapy describe hypoestrogenic adverse effects including headache, hot flashes, vaginal dryness, reduced libido, and mood changes. Reversible bone mineral density loss of approximately 2–8% after six months is reported; this is generally mild‑to‑moderate and reverses on stopping treatment. These data pertain to long‑acting analogs/depot formulations rather than native gonadorelin, but they contextualize the endocrine consequences of sustained GnRH receptor modulation (resta2023gonadotropinreleasinghormone(gnrh)gnrh pages 4-4).

• Human rare serious events reported with GnRH analogs (mostly depot): Case‑based literature and review summaries document pseudotumor cerebri, arterial hypertension (including reversible left ventricular hypertrophy), slipped capital femoral epiphysis (SCFE), and sterile injection‑site abscesses. These are characterized as rare or infrequent and can be clinically significant; they have been reported predominantly with depot agonists rather than native gonadorelin.

Embedded summary table

Clinical interpretation

• For native gonadorelin (as used diagnostically or in pulsatile therapy), the most consistently reported side effects are mild and transient (headache, flushing, nausea, local swelling; rhinitis for nasal formulations). Quantitative incidence data were not identified in the retrieved sources; frequency is qualitatively “common.” Severity is typically mild, with spontaneous resolution.
• Severe hypersensitivity/anaphylaxis to IV gonadorelin is possible but appears exceedingly rare; any parenteral administration should be prepared to manage anaphylaxis.
• Adverse effects reported for long‑acting GnRH analogs (e.g., hot flashes, mood changes, BMD loss; rare pseudotumor cerebri, hypertension, SCFE, sterile abscess) should not be assumed for native gonadorelin but illustrate class effects under sustained receptor modulation. The BMD reduction magnitude with analogs is on the order of 2–8% at six months and is reversible (resta2023gonadotropinreleasinghormone(gnrh)gnrh pages 4-4,, ).

Limitations

• Within the retrieved corpus, no primary animal toxicology data specific to native gonadorelin were found; thus, animal adverse effects, frequency, or severity could not be summarized. Human quantitative incidence data for native gonadorelin were also sparse; qualitative frequency terms from reviews are provided instead gnrh pages 4-4).

Contraindications#

Plan status: We defined the scope (gonadorelin/Factrel contraindications and interactions, including mechanistic/theoretical), searched for authoritative labels and clinical references, and gathered mechanistic evidence. Direct access to labeled prescribing information was not obtained in the retrieved corpus; therefore, the answer emphasizes mechanism-based cautions and explicitly flags the limitation. Where possible, statements are tied to the available mechanistic source.

Summary

• No explicit label-level contraindication or drug–drug interaction statements for gonadorelin were retrievable in the tool results. The following cautions and potential interactions are derived mechanistically from evidence that GnRH (gonadorelin) has extrapituitary actions in reproductive tissues, influences steroidogenesis via PLC/PKC pathways, can down-regulate gonadotropin receptors/enzymes, and that bioactive GnRH-like peptides are present in milk, implying potential exposure during lactation (mechanistic evidence).

Contraindications/cautions (mechanism-informed)

• Pregnancy: Extrapituitary GnRH signaling influences implantation, cell proliferation/apoptosis, and steroidogenesis; bioactive peptides appear in milk, indicating biological activity in reproductive contexts. Use during pregnancy should be avoided unless clearly indicated for diagnostic necessity, given potential theoretical effects on embryo/placental processes (mechanistic caution).
• Lactation: Presence of GnRH-like bioactive peptides in milk suggests potential exposure to the infant; avoid or use with caution unless clearly necessary (mechanistic caution).
• Known or suspected hormone‑sensitive reproductive tumors or active proliferative gynecologic conditions: GnRH signaling in reproductive tissues can exert antiproliferative or context-dependent effects via PKC/G-protein pathways; stimulation testing or therapeutic pulses could theoretically perturb tumor biology; specialist input advised (mechanistic caution).
• Pituitary adenomas: Because gonadorelin acutely stimulates LH/FSH via pituitary GnRH receptors, caution is reasonable in macroadenomas where abrupt secretagogue testing might theoretically exacerbate symptoms; specialist supervision recommended (mechanistic rationale tied to GnRH pituitary action and tissue-specific signaling noted in tumors).

Drug interactions Established: Not identified in the retrieved evidence corpus. The following are mechanism-based predictions.

• Sex steroids (estrogens, progestins, androgens): Feedback by sex steroids and gonadal peptides modulates GnRH–gonadotropin axis; exogenous sex steroids may blunt or alter LH/FSH responses to diagnostic gonadorelin or modify therapeutic efficacy (mechanistic).
• GnRH analogues/antagonists: Prior or concurrent GnRH agonists may down-regulate pituitary GnRH receptors; antagonists block the receptor. Either could diminish or abolish LH/FSH responses to native gonadorelin or alter therapeutic effects (mechanistic, receptor/signaling regulation).
• Dopamine pathway drugs (dopamine agonists/antagonists) and hyperprolactinemia context: Prolactin and dopaminergic tone influence reproductive axis; while not directly demonstrated here, altered prolactin signaling can modulate gonadotroph responsiveness. Expect variable responses to gonadorelin in the presence of dopamine agonists/antagonists or hyperprolactinemia (mechanistic extrapolation from GnRH axis regulation discussed alongside steroid feedback).
• Glucocorticoids and other HPG‑axis suppressants (e.g., chronic opioids): Systemic stress hormones and certain CNS-active agents suppress GnRH pulsatility; these could blunt responses to gonadorelin stimulation or reduce effectiveness of pulsatile therapy (mechanistic extrapolation aligned with GnRH axis modulators).
• Agents affecting Gq/PLC/PKC or Gi signaling: GnRH receptor couples to PLC/PKC and, in certain tumors/tissues, to pertussis toxin–sensitive G proteins; drugs that markedly modulate these pathways could theoretically alter gonadotroph or extrapituitary responses to gonadorelin (mechanistic).

Operational considerations

• Diagnostic testing: Withhold drugs likely to confound LH/FSH responses (sex steroids, recent GnRH analogues/antagonists) when clinically feasible; interpret results cautiously in settings of endocrine disorders that modulate the axis (mechanistic).
• Therapeutic pulsatile use: Anticipate attenuated efficacy if concurrent therapies suppress GnRH receptor signaling or pituitary responsiveness; monitor clinical/biochemical response and adjust (mechanistic).

Limitations

• The retrieved corpus did not include FDA/DailyMed or SmPC label texts for gonadorelin; explicit labeled contraindications and interactions could not be confirmed here. The above represent mechanism-based cautions supported by evidence of extrapituitary GnRH biology, presence in milk, and receptor/signaling behavior; clinical decisions should be cross-checked against the most recent local product labeling and authoritative drug references.

Toxicology#

Objective: Provide toxicological data for gonadorelin, including LD50 values, organ toxicity from repeat-dose studies, mutagenicity testing, and dose–response relationships.

Evidence Gaps#

• Human adverse event data is limited to anecdotal reports
• Systematic adverse event monitoring has not been conducted
• Drug interaction studies are incomplete
• Long-term safety profiles are unknown

Related Reading#

• Gonadorelin overview and research guide
• Gonadorelin dosing protocols
• Gonadorelin risks and legal status